ONVO organovo.com Net earnings per share for the last 12 months

Public company logo of Organovo Holdings, Inc. (ONVO)

Organovo Holdings, Inc. (ONVO) management possesses strong scientific potential, yet has not yet converted research into profit. Net income per share dynamics confirm this thesis, with the value stabilizing at -10.42. A team of elite bioprinting engineers stabilizes the situation, while operational processes strictly comply with FDA medical standards for biomaterial disposal.

ONVO (Organovo Corp) Net earnings per share (EPS TTM) history from 07/04/2022 to 04/24/2025

Analytical breakdowns and data insights for company Organovo Corp (ONVO)

- stock price and consensus target price:
Fundamental company valuation:Organovo Holdings (ONVO)
Mass-produced product of Organovo Holdings Inc

Earnings per share (EPS) serves as a key indicator of capital efficiency in fundamental analysis. The net income per share trend over the last four quarters visualizes the actual speed of profit generation. This metric is calculated by dividing the bottom-line financial result by the total number of outstanding securities. For Organovo Holdings, Inc. (ONVO), this figure reflects the high cost of R&D developments. Negative values confirm the absence of commercial revenue and the risk of depleting reserves during tissue bioprinting.

Competitors of Organovo Holdings, Inc.

Ascendis - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Madrigal Pharma|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Inc|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (Crinetics Pharmaceuticals, Inc.)|Earnings per share for the last twelve months newamsterdampharma.com NAMS|Soleno Therapeutics Corp (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Radius Recycling, Inc. RDUS